StocksMedium•5 November 2026•
1 min read
Collegium Pharmaceutical Raises Guidance After Q3 Earnings Beat
Key Facts
1Collegium Pharmaceutical reported Q3 2026 sales of $216.3 million, meeting analyst expectations.
2The company issued full-year revenue guidance of $840 million at the midpoint, 0.8% above consensus estimates.
3Non-GAAP profit reached $1.96 per share, surpassing analyst projections by 5.6%.
Collegium Pharmaceutical reported Q3 2026 sales of $216.3 million, meeting analyst expectations according to StockStory. Non-GAAP profit reached $1.96 per share, surpassing market projections by 5.6%.
The company issued updated full-year revenue guidance of $840 million at the midpoint, which is 0.8% above consensus estimates. COLL shares closed at $23.67 on November 4, 2026, having traded between a low of $23.42 and a high of $24.48 during that session.